Tetrindole

Tetrindole
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • 2,3,3a,4,5,6-Hexahydro-8-cyclohexyl-1H-pyrazino[3,2,1-j,k]carbazole
PubChem CID
ChemSpider
ChEBI
Chemical and physical data
FormulaC20H26N2
Molar mass294.442 g·mol−1
3D model (JSmol)
SMILES
  • C1CCC(CC1)C2=CC3=C(C=C2)N4CCNC5C4=C3CCC5
InChI
  • InChI=1S/C20H26N2/c1-2-5-14(6-3-1)15-9-10-19-17(13-15)16-7-4-8-18-20(16)22(19)12-11-21-18/h9-10,13-14,18,21H,1-8,11-12H2 checkY
  • Key:AUXCHYJDVJZEPG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Tetrindole was a drug candidate that functions by reversibly inhibiting monoamine oxidase A; it was first synthesized in Moscow in the early 1990s.[1] Tetrindole is similar in its chemical structure to pirlindole (Pyrazidol), and metralindole.[2]

References

  1. ↑ Medvedev AE, Kirkel AA, Kamyshanskaya NS, Moskvitina TA, Axenova LN, Gorkin VZ, et al. (January 1994). "Monoamine oxidase inhibition by novel antidepressant tetrindole". Biochemical Pharmacology. 47 (2): 303–8. doi:10.1016/0006-2952(94)90021-3. PMID 8304974.
  2. ↑ Ramsay RR, Gravestock MB (March 2003). "Monoamine oxidases: to inhibit or not to inhibit". Mini Reviews in Medicinal Chemistry. 3 (2): 129–36. doi:10.2174/1389557033405287. PMID 12570845.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.